[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]
[IPk] Anyone heard about this implantable sensor?
SMSI Demonstrates Breakthrough
Non-Invasive Glucose Monitoring In Vivo
Sensors for Medicine and Science, Inc. (SMSI) is developing breakthrough
chemical sensing technology for medical diagnostic, consumer and industrial
applications. The Company is pursuing significant product opportunities,
which are enabled for the first time by this optical technology.
SMSI's primary focus is on the development of an implanted, rice-grain
sized, continuous glucose monitor that is remotely powered and interrogated.
Initial pre-clinical testing of the device has demonstrated in vivo
proof-of- concept over an extended time period, with high correlation to YSI
"gold standard" glucose readings. The device is moving into full-scale
pre-clinical testing. SMSI is actively pursuing potential partnerships for
the clinical development and commercialization of the product.
Another significant product opportunity enabled by this technology is a fast
response oxygen sensor. This sensor does not consume oxygen and enables real
time, breath-by-breath analysis for critical care, respiratory function and
metabolic applications. SMSI has partnered one respiratory application for
the oxygen sensor. This application is currently in field-testing, with full
commercialization planned for 2002.
Significant advances achieved by the SMSI technology platform include high
sensitivity, very fast response times, low power consumption, ease of
miniaturization, high volume manufacturability utilizing standard
technologies, and excellent reliability. Two key breakthroughs of this
technology are: 1) it offers highly sensitive/accurate readings while
simultaneously providing one of the fastest response times in the industry,
and 2) it can both power the sensor, and read results, remotely. The Company
believes that the breadth of potential applications for this technology will
enable SMSI to selectively:
* Create new markets
* Displace existing technology in current markets
* Provide a competitive advantage to licensees within existing product
SMSI's initial strategy is to focus on the development of health related
applications for its technology. The Company has developed proprietary
indicator chemistry that enables the patented sensor platforms to be easily
adapted to measure other high-value molecules (analytes) of interest beyond
glucose and oxygen. The additional applications will enable SMSI to leverage
its sensor platforms across a diverse set of market opportunities.
In order to realize value from product applications other than glucose and
oxygen, management intends to grant licenses in clearly defined fields of
use to interested companies that serve the relevant markets.
SOURCE Sensors for Medicine and Science, Inc.
CONTACT: Marc R. Schneebaum, President and CEO, or Carroll Cummings,
Administrator, of Sensors for Medicine and Science, Inc., +1-301-515-7260
Web site: http://www.s4ms.com
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
help SUPPORT Insulin Pumpers http://www.insulin-pumpers.org/donate.shtml